Breaking News

Financial Report: BMS

April 29, 2014

Eliquis and AZ diabetes deal drive earnings in the quarter

BMS
 
1Q Revenues: $3.8 billion (-1%)

1Q Earnings: $936 million (+54%)

Comments: The company completed the sale of its diabetes business to AstraZeneca, receiving $3.3 billion in closing and milestone payments during the quarter. Sprycel sales were up 19% to $342 million. Yervoy sales grew 18% to $271 million. Orencia sales were up 13% to $363  million, and Baraclude sales grew 11% to 406 million. Sustiva franchise sales were down 18% to $319 million due to generic competition. Global revenues for Eliquis were $106 million in the quarter, up from $22 million in 1Q13. R&D expenses increased 2% to $946 million in the quarter.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision